Postvaccinal encephalitis after ChAdOx1 nCov-19
Zuhorn F, Graf T, Klingebiel R, Schäbitz WR and Rogalewski A
Postvaccinal encephalitis after ChAdOx1 nCov-19
Zuhorn F, Graf T, Klingebiel R, Schäbitz WR and Rogalewski A
The global SARS-CoV-2 pandemic has contributed to more than 163 million confirmed infections and 3.3 million deaths worldwide. The severity of the pandemic has led to an unprecedented effort to develop multiple effective vaccines. Due to excellent safety and efficacy data from clinical trials, several vaccines were approved. We report a case series of postvaccinal encephalitis in temporal correlation to vaccination with ChAdOx1 nCov-19. The diagnostic criteria for possible autoimmune encephalitis were fulfilled. Our patients responded well to immunosuppressive therapy with corticosteroids. The incidence has been estimated to be approximately 8 per 10 million vaccine doses. Complication of postvaccinal encephalitis after ChAdOx1 nCoV-19 vaccination still appear to be very rare, but need to be diagnosed and treated adequately. Large pooled data from observational epidemiologic studies are necessary to verify causality. This article is protected by copyright. All rights reserved.
Impact of COVID-19 pandemic on people with epilepsy: An interventional study using early physical consultation
Koh MY, Lim KS, Fong SL, Khor SB and Tan CT
Impact of COVID-19 pandemic on people with epilepsy: An interventional study using early physical consultation
Koh MY, Lim KS, Fong SL, Khor SB and Tan CT
Telehealth use is limited in developing countries. Therefore, a modified approach with early physical consultation was designed and applied in our hospital. This study aimed to determine the efficacy of this early physical consultation in reducing the clinical and psychological impacts of coronavirus disease-19 (COVID-19), which enabled insight into its global feasibility.
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021
Ehde DM, Roberts MK, Humbert AT, Herring TE and Alschuler KN
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021
Ehde DM, Roberts MK, Humbert AT, Herring TE and Alschuler KN
Multiple sclerosis (MS) organizations have recommended that adults with MS obtain the COVID-19 vaccination. Vaccine hesitancy is a barrier to full COVID-19 inoculation in the general population. Whether vaccine hesitancy is also a barrier towards optimizing vaccination rates in the MS community is unknown. To investigate vaccine hesitancy and inform efforts to increase vaccine uptake in the MS population, we conducted a follow up survey of a national sample of adults with MS living in the United States who completed an initial survey early in the COVID-19 pandemic. The current study aimed to answer questions vital to understanding vaccine hesitancy, specifically: (1) What is the prevalence of COVID-19 vaccine hesitancy in early 2021? (2) What are the reasons for and factors associated with current hesitancy? (3) How has vaccine willingness and hesitancy changed from April/May 2020 to January/February 2021? and (4) Who has changed in their vaccine willingness?
Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination
Vogrig A, Janes F, Gigli GL, Curcio F, Negro ID, D’Agostini S, Fabris M and Valente M
Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination
Vogrig A, Janes F, Gigli GL, Curcio F, Negro ID, D’Agostini S, Fabris M and Valente M
Several central and peripheral nervous system complications associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection have been recently described. An effective mass vaccination program is necessary to effectively reduce infection spread and, consequently, limit long-term sequelae, including those affecting the nervous system. Nevertheless, as more patients gain access to coronavirus disease 2019 (COVID-19) vaccines, it is important to report potential adverse events. Herein, we report a patient with previous history of post-infectious rhombencephalitis who developed an acute disseminated encephalomyelitis (ADEM) two weeks after being vaccinated for COVID-19.
Severe COVID-19 and Stroke-Another Piece in the Puzzle
Robinson CP and Busl KM
Severe COVID-19 and Stroke-Another Piece in the Puzzle
Robinson CP and Busl KM
